Free Trial

Verve Therapeutics (VERV) Competitors

Verve Therapeutics logo
$5.73
-0.06 (-1.04%)
(As of 10/31/2024 ET)

VERV vs. HRMY, KNSA, MIRM, ARVN, WVE, NRIX, RXRX, OCUL, NAMS, and TECX

Should you be buying Verve Therapeutics stock or one of its competitors? The main competitors of Verve Therapeutics include Harmony Biosciences (HRMY), Kiniksa Pharmaceuticals (KNSA), Mirum Pharmaceuticals (MIRM), Arvinas (ARVN), Wave Life Sciences (WVE), Nurix Therapeutics (NRIX), Recursion Pharmaceuticals (RXRX), Ocular Therapeutix (OCUL), NewAmsterdam Pharma (NAMS), and Tectonic Therapeutic (TECX). These companies are all part of the "pharmaceutical products" industry.

Verve Therapeutics vs.

Verve Therapeutics (NASDAQ:VERV) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, community ranking, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Verve Therapeutics presently has a consensus price target of $26.00, suggesting a potential upside of 349.83%. Harmony Biosciences has a consensus price target of $47.00, suggesting a potential upside of 43.95%. Given Verve Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Verve Therapeutics is more favorable than Harmony Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Verve Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Harmony Biosciences
2 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.56

In the previous week, Harmony Biosciences had 18 more articles in the media than Verve Therapeutics. MarketBeat recorded 32 mentions for Harmony Biosciences and 14 mentions for Verve Therapeutics. Harmony Biosciences' average media sentiment score of 0.85 beat Verve Therapeutics' score of 0.34 indicating that Harmony Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Verve Therapeutics
2 Very Positive mention(s)
2 Positive mention(s)
9 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Harmony Biosciences
12 Very Positive mention(s)
4 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Harmony Biosciences has a net margin of 17.53% compared to Verve Therapeutics' net margin of -933.08%. Harmony Biosciences' return on equity of 22.97% beat Verve Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Verve Therapeutics-933.08% -35.20% -27.54%
Harmony Biosciences 17.53%22.97%13.96%

97.1% of Verve Therapeutics shares are owned by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are owned by institutional investors. 19.3% of Verve Therapeutics shares are owned by company insiders. Comparatively, 30.8% of Harmony Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Harmony Biosciences has higher revenue and earnings than Verve Therapeutics. Verve Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verve Therapeutics$20.65M23.44-$200.07M-$2.59-2.21
Harmony Biosciences$656.11M2.86$128.85M$1.9516.91

Harmony Biosciences received 32 more outperform votes than Verve Therapeutics when rated by MarketBeat users. Likewise, 66.25% of users gave Harmony Biosciences an outperform vote while only 50.00% of users gave Verve Therapeutics an outperform vote.

CompanyUnderperformOutperform
Verve TherapeuticsOutperform Votes
21
50.00%
Underperform Votes
21
50.00%
Harmony BiosciencesOutperform Votes
53
66.25%
Underperform Votes
27
33.75%

Verve Therapeutics has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500. Comparatively, Harmony Biosciences has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500.

Summary

Harmony Biosciences beats Verve Therapeutics on 13 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VERV vs. The Competition

MetricVerve TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$484.06M$7.14B$5.37B$8.40B
Dividend YieldN/A8.77%5.21%4.20%
P/E Ratio-2.2116.47140.7317.73
Price / Sales23.44254.681,437.0778.19
Price / CashN/A50.1638.9433.56
Price / Book0.785.684.744.59
Net Income-$200.07M$151.16M$115.38M$225.45M
7 Day PerformanceN/A-1.43%-0.60%-0.22%
1 Month Performance18.18%6.29%3.92%1.93%
1 Year Performance-52.49%40.64%39.36%33.41%

Verve Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VERV
Verve Therapeutics
2.1094 of 5 stars
$5.73
-1.0%
$26.00
+353.8%
-38.5%$484.90M$20.65M-2.21110Upcoming Earnings
HRMY
Harmony Biosciences
4.8984 of 5 stars
$34.05
flat
$44.38
+30.3%
+71.5%$1.93B$656.11M17.46200Earnings Report
Analyst Forecast
Short Interest ↓
Analyst Revision
News Coverage
Gap Down
KNSA
Kiniksa Pharmaceuticals
2.6195 of 5 stars
$26.92
+0.3%
$33.60
+24.8%
+46.7%$1.91B$338.93M-168.24220Earnings Report
Analyst Forecast
Analyst Revision
News Coverage
MIRM
Mirum Pharmaceuticals
4.6843 of 5 stars
$39.36
+2.4%
$56.82
+44.4%
+43.8%$1.86B$264.38M-17.19140Upcoming Earnings
News Coverage
Positive News
ARVN
Arvinas
2.2793 of 5 stars
$26.94
+1.6%
$57.69
+114.2%
+83.4%$1.84B$93.30M-5.21445Earnings Report
Analyst Forecast
Short Interest ↓
News Coverage
Gap Down
WVE
Wave Life Sciences
4.9621 of 5 stars
$14.82
+1.0%
$19.44
+31.2%
+163.7%$1.82B$110.50M-26.00240Analyst Forecast
NRIX
Nurix Therapeutics
1.5958 of 5 stars
$25.22
+1.8%
$29.40
+16.6%
+357.6%$1.81B$76.99M-8.67300
RXRX
Recursion Pharmaceuticals
2.8722 of 5 stars
$6.36
+0.5%
$9.40
+47.8%
+25.8%$1.79B$44.58M-3.93400Upcoming Earnings
OCUL
Ocular Therapeutix
4.2742 of 5 stars
$10.89
+0.3%
$16.57
+52.2%
+348.6%$1.76B$58.44M-8.07267Upcoming Earnings
Short Interest ↓
NAMS
NewAmsterdam Pharma
3.2983 of 5 stars
$18.86
-2.3%
$33.80
+79.2%
+151.0%$1.70B$7.42M0.0057Upcoming Earnings
Short Interest ↑
TECX
Tectonic Therapeutic
3.4746 of 5 stars
$36.40
+5.5%
$60.00
+64.8%
N/A$1.63BN/A-7.04120

Related Companies and Tools


This page (NASDAQ:VERV) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners